Tocotrienols in Parkinson's Disease (PD)
Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial
Sponsor: National Neuroscience Institute
Listed as NCT04491383, this PHASE2 trial focuses on Neuro-Degenerative Disease and Parkinson Disease and remains ongoing. Sponsored by National Neuroscience Institute, it has been updated 13 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Neuroscience Institute
For direct contact, visit the study record on ClinicalTrials.gov .